On March 29, 2026, the most valuable pharmaceutical company in the world made its largest-ever bet on artificial intelligence and aging.
Eli Lilly signed a drug discovery agreement with Insilico Medicine worth up to $2.75 billion, a Hong Kong-based, AI-driven biotechnology company that uses generative artificial intelligence to identify drug candidates targeting the biology of aging. The deal is not primarily about treating any one disease. It is about using AI to attack the underlying biological processes that make humans susceptible to dozens of age-related conditions at once.